文献速递流行病学与生物统计临床试验与 GCP

利用治疗交叉数据提升多人群疗效检验效率

Efficiency Enhancement in Testing Treatment Efficacy Across Multiple Populations Using Treatment Crossover Data.
PubMed 文献 · Stat Med · 2026-01-01

该研究针对2×2交叉试验提出多人群疗效评估框架,并与标准平行组分析比较效能增益。模拟实验显示交叉分析在统计功效上持续优于平行组分析,尤其当携带效应较小时;2型糖尿病临床试验应用也证实其效率优势。

要点

  • 交叉分析在2×2交叉试验中统计功效持续优于平行组分析。
  • 携带效应较小时交叉分析的效率优势更明显。
  • 2型糖尿病临床试验实例展示交叉分析的效率优势。

核心结论

  • 交叉分析可提升多人群疗效检验的统计功效,尤其携带效应较小时。

研究设计与样本

  • 针对2×2交叉试验提出多人群疗效评估框架,并与标准平行组分析比较。
  • 通过模拟实验验证方法性能,并应用于一项2型糖尿病临床试验。

主要发现

  • 模拟实验显示交叉分析在统计功效上持续优于平行组分析,尤其携带效应较小时。
  • 2型糖尿病临床试验应用展示交叉分析的效率优势。

临床怎么用

  • 在多人群疗效评估中可考虑采用2×2交叉设计以提升研究效率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in biotechnology and personalized medicine have driven the development of efficient clinical trial methodologies for assessing treatment efficacy across multiple populations defined by treatment effect modifiers. Within-patient comparison of different treatments is a promising approach for improving study efficiency across multiple populations by eliminating between-patient variability in treatment evaluation. This study provides a framework for evaluating treatment efficacy in multiple populations for 2 × 2 $$ 2\times 2 $$ crossover trials and evaluates the efficacy gain in comparison with the standard parallel-group analysis. Simulation experiments confirm that the crossover analysis consistently outperforms the parallel-group analysis in statistical power, especially when carryover effects are small. An application to a clinical trial in Type 2 diabetes demonstrates the efficiency advantages of the crossover analysis. These numerical results emphasize the potential of the crossover analysis for enhancing the efficiency of clinical development of personalized medicine.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Emoto R, Ishii K, Takamura T, et al. Efficiency Enhancement in Testing Treatment Efficacy Across Multiple Populations Using Treatment Crossover Data. Stat Med. 2026. PMID: 42455565. doi:10.1002/sim.70651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。